Patents by Inventor Vincent Lotteau

Vincent Lotteau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230181539
    Abstract: Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new beta-coronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that BAY-2402234 is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.
    Type: Application
    Filed: May 19, 2021
    Publication date: June 15, 2023
    Inventors: Pierre-Olivier VIDALAIN, Antoine NOUGAIREDE, Franck TOURET, Patrice ANDRE, Vincent LOTTEAU, Xavier Nicolas LAMBALLERIE, Yves Louis JANIN
  • USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230146096
    Abstract: Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 11, 2023
    Inventors: Pierre-Olivier VIDALAIN, Vincent LOTTEAU, Patrice ANDRE, Franck TOURET, Xavier Nicolas DE LAMBALLERIE, Antoine NOUGAIREDE
  • USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS
    Publication number: 20230060715
    Abstract: The present invention relates to the use of a farnesoid X receptor (FXR) agonist for the treatment of hepatitis D infection.
    Type: Application
    Filed: January 14, 2021
    Publication date: March 2, 2023
    Inventors: RAPHAËL DARTEIL, JULIE LUCIFORA, DAVID DURANTEL, CHRISTOPHE RAMIERE, BENOÎT LACOMBE, VINCENT LOTTEAU, PATRICE ANDRE
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING PERSISTENCE AND EXPRESSION OF EPISOMAL VIRUSES
    Publication number: 20210085662
    Abstract: The inventors surprisingly found that FXR plays a determinant role in the maintenance of viral episome in cells from tissues that are not specialized in bile salt synthesis and transport as the liver or the intestine. In particular, the inventors show that FXR agonist could be suitable for inhibiting the replication of viruses (e.g. BKV and HIV-1) that persist in the cell in an episomal and extrachromosomal form of DNA. Accordingly the present invention relates to a method of reducing persistence and expression of an episomal virus in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of a FXR agonist.
    Type: Application
    Filed: March 29, 2018
    Publication date: March 25, 2021
    Inventors: Vincent LOTTEAU, Patrice ANDRE
  • Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
    Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20180169115
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: February 19, 2018
    Publication date: June 21, 2018
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
    Patent number: 9895380
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Direct protein delivery with engineered microvesicles
    Patent number: 9695446
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: July 4, 2017
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau
  • Methods and Pharmaceutical Composition for the Treatment of Polyomavirus Infections
    Publication number: 20160250245
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of polyomavirus infections. In particular, the present invention relates to a method for treating a polyomavirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of gemcitabine.
    Type: Application
    Filed: October 20, 2014
    Publication date: September 1, 2016
    Inventors: Vincent Lotteau, Patrice Andre, Benoit De Chassey, Laurene Meyniel-Schicklin, Irene Pilar Castellanos
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
    Publication number: 20160220586
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Application
    Filed: September 10, 2014
    Publication date: August 4, 2016
    Inventors: PATRICE ANDRE, VINCENT LOTTEAU, PAULINE RADREAU, MARINE GILARDONE, AMAURY PATIN, DIDIER ROCHE, DANIEL CRAVO, SOPHIE HALLAKOU-BOZEC
  • Methods and pharmaceutical compositions for inhibiting influenza viruses replication
    Patent number: 9168236
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?-monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: October 27, 2015
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard - Lyon 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • Reprogrammation of Eukaryotic Cells with Engineered Microvesicles
    Publication number: 20140356943
    Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 4, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
  • METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS
    Publication number: 20140296106
    Abstract: The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus.
    Type: Application
    Filed: May 16, 2012
    Publication date: October 2, 2014
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Chantal Rabourdin-Combe, Lionel Tafforeau, Thibault Chantier, Anne Aublin-Gex
  • Direct Protein Delivery with Engineered Microvesicles
    Publication number: 20140242107
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 28, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau
  • Reprogrammation of eukaryotic cells with engineered microvesicles
    Patent number: 8716020
    Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: May 6, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
  • Direct protein delivery with engineered microvesicles
    Patent number: 8697439
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 15, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION
    Publication number: 20140030224
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 30, 2014
    Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • METHOD FOR INCREASING THE REPLICATION CAPACITY OF AN INFLUENZA VIRUS IN CULTURED CELLS
    Publication number: 20140024101
    Abstract: The present invention relates to methods for increasing the replication capacity of an influenza virus in cultured cells. More particularly, the present invention relates to a method for increasing the replication capacity of an influenza virus in a cell comprising the steps consisting of i) infecting said cell with said influenza virus and ii) culturing said infected cell with a least one molecule selected from the group consisting of Dibucaine, Aprindine, Amiloride, Mevinolin, Simvastatin, Promathazine, Pranlukast, Nimodipine, Ibutilide hemifumarate Salt, Risperidone and derivatives or analogues thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 23, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • REPROGRAMMATION OF EUKARYOTIC CELLS WITH ENGINEERED MICROVESICLES
    Publication number: 20130034900
    Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.
    Type: Application
    Filed: November 10, 2010
    Publication date: February 7, 2013
    Applicant: INSERM (Institut National de la Sante et de la Recherche Midicale)
    Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
  • DIRECT PROTEIN DELIVERY WITH ENGINEERED MICROVESICLES
    Publication number: 20120322147
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Application
    Filed: November 10, 2010
    Publication date: December 20, 2012
    Applicant: INSERM(institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau